SynthesisThe European respiratory journal2023
Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis.
Abstract readMeta-AnalysisSystematic ReviewLetter
In one paragraph
Synthesis in The European respiratory journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of all-oral bedaquiline-based shorter regimens in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.BMJ global health · 2025Pooled it
- Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis.The European respiratory journal · 2023Pooled it
- We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Characteristics, Treatment Strategies, and Long-term Health Outcomes of People With Bedaquiline-resistant Tuberculosis in Karakalpakstan, Uzbekistan-A Retrospective Cohort Study.Open forum infectious diseases · 2026Article
- Role of casual contact in drug-resistant tuberculosis transmission: a molecular epidemiology study.American journal of respiratory and critical care medicine · 2026Article
- Rising bedaquiline resistance: exploring potential causes and next steps.The European respiratory journal · 2026Article
- Bedaquiline and linezolid resistance in people with rifampicin-resistant tuberculosis in the Western Cape Province of South Africa.Research square · 2026Article
- Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022-2024.Open forum infectious diseases · 2026Article
- Advancing Tuberculosis Treatment with Next-Generation Drugs and Smart Delivery Systems.Pharmaceutics · 2026Review
- Bedaquiline Resistance: A Looming Global Threat in Tuberculosis Management.Current microbiology · 2025Review
- Article
- Extensively Drug-Resistant Tuberculosis with Conflicting Resistance Testing Results, Lesotho.Emerging infectious diseases · 2025Article
- New Triazolopyrimidines with Improved Activity againstACS medicinal chemistry letters · 2025Article
- Clinical best practices for caring for people with expanded resistance to newer TB drugs.IJTLD open · 2025Review
- Identification of novelFuture medicinal chemistry · 2025Article
- REVOLUTIONIZING TUBERCULOSIS REGIMEN DEVELOPMENT.Transactions of the American Clinical and Climatological Association · 2025Review
- Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study.The Lancet. Global health · 2024Article
- Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance.Emerging infectious diseases · 2024Article
- A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing forThe European respiratory journal · 2024Article
- Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia.Emerging infectious diseases · 2024Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Rubeshan PerumalCAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa rubeshanperumal@gmail.com.ORCID 0000-0001-8892-2904
Neda BionghiDepartment of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, USA.
Camus NimmoFrancis Crick Institute, London, UK.ORCID 0000-0001-7355-4651
Marothi LetsoaloCAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Matthew J CummingsDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Madeleine HopsonDepartment of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, USA.ORCID 0000-0002-4585-8727
Allison WolfDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Shamim Al JubaerDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Nesri PadayatchiCAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Kogieleum NaidooCAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Michelle H LarsenDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Max O'DonnellCAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Funding
Novel Reporter Phages to Detect Complex TB Drug Resistance and PersistenceR01AI114900 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Michelle H Larsen, Max O'Donnell · 2015 to 2026
$7.2MRapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phageR01AI176407 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Max O'Donnell · 2023 to 2026
$3.0MAdaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South AfricaR01AI167795 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Max O'Donnell · 2022 to 2026
$2.9MNIAID NIH HHS R01 AI114900NIAID NIH HHS R01 AI167795NIAID NIH HHS R01 AI176407
Abstract
PubMed holds no abstract for this paper.
Indexed as
Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsDiarylquinolinesHumansAntitubercular AgentsbedaquilineDiarylquinolines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.